Investor AB: The Balance Sheet That Proved Its Point

The most important takeaway is simple: Investor delivered a 7 percent total return to shareholders in the first quarter while the Swedish stock market index fell by 1 percent. That is an 8-percentage point gap in just three months. Adjusted NAV, the estimated value of all holdings minus debt, rose 3 percent to SEK 367 per share. The B share closed at SEK 381.70 on April 20, meaning investors were paying roughly a 4 percent premium to the latest reported NAV. That NAV is about three weeks old, so the actual figure could have shifted depending on how the underlying holdings have moved since March 31. Either way, the market is giving Investor credit for what it owns, and then some.

The listed portfolio, including ABB, Saab, AstraZeneca, and others, delivered a 5 percent total return in the quarter. Saab led the way, up nearly 14 percent, supported by continued defense spending momentum across Europe. ABB contributed 10 percent. These are significant positions, and they have a meaningful impact. Patricia Industries, the private investment arm, added 4 percent, partly due to the strengthening of the US dollar during the quarter, which flattered the translation of dollar-denominated earnings back into kronor. Organic sales growth across the private companies came in at 3 percent in constant currency, which was solid if unspectacular.

Then there is EQT, the global private equity manager in which Investor is a founding shareholder. That segment was weaker, with a 13 percent negative value change reducing NAV by SEK 13.8 billion, almost entirely driven by EQT AB's share price falling 22 percent in the quarter. On the positive side, gross cash increased to SEK 37.4 billion, while leverage, measured as net debt as a share of total assets, fell to just 1.2 percent. The balance sheet remains in excellent shape.

At first glance, the EQT segment looks like a significant problem, and a SEK 14.4 billion decline in a single quarter is hard to ignore. On closer inspection, however, the picture is less negative. Investor used the weakness to add SEK 1.4 billion of EQT AB shares at lower prices, while the underlying fund investments actually edged higher. The bigger issue is the size of the EQT position itself. At current values, it accounts for around 8 percent of Investor’s total assets, which means a prolonged fall in EQT AB’s share price would keep weighing on reported NAV even if the rest of the portfolio performs well. That is the risk most analyst commentary still seems to underappreciate.

Most large European holding companies struggled in Q1 2026 as tariff fears affected industrial and healthcare stocks. Investor's diversification across listed equities, private businesses, and alternative assets acted as a genuine cushion. Companies such as Mölnlycke, the wound-care business, and Nova Biomedical, the diagnostics company, generate steady cash flows that are largely unaffected by short-term market fluctuations. Currency remains the sharpest macro variable to watch. The stronger dollar was a tailwind in Q1, but the reverse is equally true, and management acknowledged this.

The Mölnlycke CEO transition is an underappreciated risk heading into the next quarter. Mölnlycke is Investor’s largest private asset, with an estimated value of SEK 82.3 billion, and it is currently being run by an interim executive while a permanent replacement is being sought. At that scale, leadership uncertainty can slow strategic decision-making at precisely the moment when tariff pressure and rising Chinese competition require the opposite.

The second thing to watch is whether Nova Biomedical’s EBITA margin, which increased from 26 percent to 32.3 percent year over year, can be sustained. That improvement is the clearest sign so far that Investor’s largest recent acquisition is starting to deliver. Two more quarters at a similar level would materially change the discussion around Patricia Industries. Until then, Q1 was strong, but the most important questions remain open.